Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma

PURPOSE: Anlotinib has achieved good results in clinical trials of a variety of cancers. However, the effects of anlotinib on the tumor microenvironment (TME) and systemic immunity have not been reported. There is an urgent need to identify the underlying mechanism to reveal new opportunities for it...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Yudong, Luo, Bingying, Lu, Yao, Wang, Daowei, Yan, Jie, Zheng, Jian, Xiao, Jun, Wang, Yangyang, Xue, Zhenyi, Yin, Jie, Chen, Peng, Li, Long, Zhao, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377760/
https://www.ncbi.nlm.nih.gov/pubmed/34844980
http://dx.doi.org/10.1158/1078-0432.CCR-21-2241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377760/
https://www.ncbi.nlm.nih.gov/pubmed/34844980
http://dx.doi.org/10.1158/1078-0432.CCR-21-2241

Ejemplares similares